Generic Name and Formulations:
Acetaminophen 10mg/mL; soln for IV infusion; preservative-free.
Indications for OFIRMEV:
Management of mild-to-moderate pain or moderate-to-severe pain with adjunctive opioid analgesics. Fever.
Ensure total amount of acetaminophen from all routes and all sources does not exceed max recommended dose. Give by IV infusion over 15 mins. <50kg: 15mg/kg every 6hrs (or 12.5mg/kg every 4hrs); max single dose: 15mg/kg (up to 750mg), max daily dose: 75mg/kg/24hrs (up to 3750mg). ≥50kg: 1000mg every 6hrs (or 650mg every 4hrs); max single dose: 1000mg, max daily dose: 4000mg/24hrs. Minimum dosing interval: 4hrs.
Ensure total amount of acetaminophen from all routes and all sources does not exceed max recommended dose. Give by IV infusion over 15 mins; place small volume doses (up to 60mL) in syringe and administer using syringe pump. Fever only: (Neonates 0–28days): 12.5mg/kg every 6hrs; max daily dose: 50mg/kg/24hrs; (Infants 29days–2yrs): 15mg/kg every 6hrs; max daily dose: 60mg/kg/24hrs. Minimum dosing interval: 6hrs. Fever/pain: (<2yrs): not established (for pain); (≥2yrs): 15mg/kg every 6hrs (or 12.5mg/kg every 4hrs); max single dose: 15mg/kg (up to 750mg), max daily dose: 75mg/kg/24hrs (up to 3750mg). Minimum dosing interval: 4hrs.
Severe hepatic impairment. Severe active liver disease.
Ensure correct prescribing, preparing, and administering to avoid dosing errors. Risk of acute liver failure (may result in liver transplant or death) associated with the use of doses higher than recommended or involving >1 acetaminophen-containing product. Hepatic impairment. Active hepatic disease. Alcoholism. Chronic malnutrition. Severe hypovolemia. Severe renal impairment (CrCl ≤30mL/min). Pregnancy. Nursing mothers.
Caution with CYP2E1 inhibitors or inducers (eg, alcohol). Doses of 4000mg/day may increase INR, monitor warfarin frequently.
Nausea, vomiting, headache, insomnia; also children: constipation, pruritus; hepatotoxicity (with high doses), hypersensitivity (discontinue if occurs); rare: serious skin reactions (eg, AGEP, Stevens-Johnson Syndrome, toxic epidermal necrolysis).
Single-dose vials or bags (100mL)—24
Neurology Advisor Articles
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- A Convenient Truth: The Problem With Seizure Under-Reporting and How to Fix It
- Incidence of Serotonin Syndrome With Co-Prescription of Triptans, Antidepressants
- Idiopathic Parkinson Disease May Increase Risk for Overactive Bladder
- Palliative Care in Movement Disorders: Recommendations for Improvement
- Cannabinoids May Be Effective as Adjunctive Treatment for Refractory Epilepsy